Cencora, Inc. $COR Shares Purchased by Vontobel Holding Ltd.

Posted by Geri Gentry on Oct 17th, 2026

Vontobel Holding Ltd. increased its stake in Cencora, Inc. (NYSE:COR – Free Report) by 7,699.9% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 250,846 shares of the company’s stock after purchasing an additional 247,630 shares during the quarter. Vontobel Holding Ltd.’s holdings in Cencora were worth $75,317,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Cencora during the 2nd quarter worth about $5,154,136,000. T. Rowe Price Investment Management Inc. boosted its stake in Cencora by 160.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after purchasing an additional 4,123,795 shares during the period. Bank of America Corp DE boosted its stake in Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after purchasing an additional 267,318 shares during the period. Amundi boosted its stake in Cencora by 43.5% in the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after purchasing an additional 676,066 shares during the period. Finally, Carmignac Gestion grew its holdings in Cencora by 58.7% during the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock valued at $494,463,000 after buying an additional 646,112 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Activity at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $324.12, for a total value of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This represents a 36.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.38% of the stock is owned by insiders.

Analyst Ratings Changes

COR has been the topic of several analyst reports. JPMorgan Chase & Co. upped their price target on Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Leerink Partners boosted their price objective on shares of Cencora from $380.00 to $388.00 and gave the company an “outperform” rating in a research note on Wednesday, October 7th. UBS Group decreased their target price on shares of Cencora from $430.00 to $400.00 and set a “buy” rating on the stock in a report on Friday. Argus lowered their target price on shares of Cencora to $340.00 and set a “buy” rating on the stock in a research note on Tuesday, June 23rd. Finally, Wells Fargo & Company increased their target price on shares of Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $363.81.

Read Our Latest Analysis on COR

Cencora Price Performance

Shares of COR traded down $0.87 during trading hours on Friday, reaching $340.54. 1,978,868 shares of the company’s stock traded hands, compared to its average volume of 1,282,490. Cencora, Inc. has a 12 month low of $244.82 and a 12 month high of $377.54. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The stock has a market cap of $64.99 billion, a PE ratio of 25.30, a price-to-earnings-growth ratio of 1.75 and a beta of 0.58. The firm’s 50 day simple moving average is $320.38 and its 200-day simple moving average is $303.34.

Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to analysts’ expectations of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same period in the prior year, the business earned $4.00 earnings per share. Equities analysts expect that Cencora, Inc. will post 17.87 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were issued a $0.60 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 17.83%.

Cencora Profile

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.